Latest news with #TSXCompanyManual
Cision Canada
6 days ago
- Business
- Cision Canada
Oncolytics Biotech® Announces Voluntary Delisting from the Toronto Stock Exchange
SAN DIEGO, Aug. 8, 2025 /CNW/ -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that the common shares in the capital of the Company (the "Shares") will be voluntarily delisted from the Toronto Stock Exchange ("TSX") at the close of markets on August 22, 2025, pursuant to the Company's application for voluntary delisting and the satisfaction of the conditions to delist from the TSX. The delisting from the TSX will not affect the Company's listing on the Nasdaq. After careful consideration, the board of Oncolytics has determined that a TSX de-listing is in the best interests of the Company and its shareholders for a number of reasons, including: The Shares are already listed and trading on the Nasdaq, and the Company intends on maintaining such listing; Oncolytics will cease to be treated as a Foreign Private Issuer (for purposes of U.S. federal securities laws) effective January 1, 2026, and is considering re-domiciling to the U.S. in the future; and the benefits associated with maintaining a secondary listing on the TSX do not justify the direct and indirect costs given Oncolytics' U.S. focus and its U.S. shareholder base. After delisting from the TSX, the Shares will continue to trade on the Nasdaq under the symbol "ONCY." Canadian shareholders will be able to continue to trade their shares on the Nasdaq through their brokers who have U.S.-registered broker-dealer affiliates. Oncolytics will continue to be a reporting issuer in the provinces and territories of Canada. Since the Shares are listed on the Nasdaq (an acceptable alternative market), shareholder approval is not required under Section 720(b) of the TSX Company Manual. About Oncolytics Biotech Inc. Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses. The Company is advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic pancreatic and breast cancers, both of which have received Fast Track designation from the FDA, and other gastrointestinal tumors. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: or follow the Company on social media on LinkedIn and on X @ oncolytics. Forward-looking statements This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward- looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential, mechanism of action and benefits of pelareorep as a cancer therapeutic; our goals, strategies and objectives; our active pursuit of strategic partnerships; our plans to delist from the TSX and remain listed on the Nasdaq; our foreign private issuer status; and any potential re-domiciling transaction. In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. These statements involve known and unknown risks and uncertainties that may cause actual results to differ materially from those anticipated. These risks include, but are not limited to, regulatory outcomes, trial execution, financial resources, and market dynamics. Please refer to Oncolytics' public filings with securities regulators in the U.S. and Canada for more information. The Company assumes no obligation to update forward-looking statements, except as required by law. Company Contact Jon Patton Director of IR & Communication [email protected] Investor Relations for Oncolytics Mike Moyer LifeSci Advisors +1-617-308-4306 [email protected] Media Contact for Oncolytics
Toronto Star
06-08-2025
- Business
- Toronto Star
Stingray Announces Election of Directors
MONTREAL, Aug. 06, 2025 (GLOBE NEWSWIRE) — In accordance with the TSX Company Manual, Stingray Group Inc. (TSX: RAY.A; RAY.B) (the 'Corporation') is issuing this news release to disclose the voting results for the election of directors at its annual general meeting of shareholders held virtually earlier today. Each of the following ten (10) nominees proposed by the Corporation was duly elected as director of the Corporation by the votes cast at the meeting. The results of the vote are as follows:
Hamilton Spectator
28-07-2025
- Business
- Hamilton Spectator
Globex Mining Enterprises Inc. Announces Renewal of Normal Course Issuer Bid
ROUYN-NORANDA, Québec, July 28, 2025 (GLOBE NEWSWIRE) — GLOBEX MINING ENTERPRISES INC. (GMX – Toronto Stock Exchange, G1MN – Frankfurt, Stuttgart, Berlin, Munich, Tradegate, Lang & Schwarz Stock Exchanges and GLBXF – OTCQX International) is pleased to announce that the Toronto Stock Exchange ('TSX') has approved the renewal of Globex's normal course issuer bid ('NCIB'). Under the renewed NCIB, Globex will be entitled to repurchase for cancellation up to 1,000,000 common shares, representing approximately 1.78% of Globex's issued and outstanding shares as of July 21, 2025, over a twelve-month period starting on August 2, 2025 and ending on August 1, 2026. The purchases by Globex will be effected through the facilities of the TSX and on alternative trading systems in Canada, and will be made at the market price of the shares at the time of the purchase. Globex had 56,095,636 common shares issued and outstanding as of July 21, 2025, of which 48,662,545 shares constituted the 'public float'. During the most recently completed six months, the average daily trading volume for Globex's common shares on the TSX was 31,900 shares. Consequently, under the policies of the TSX, Globex will have the right to repurchase during any one trading day a maximum of 7,975 common shares on the TSX, representing 25% of the average daily trading volume. In addition, Globex may make, once per calendar week, a block purchase (as such term is defined in the TSX Company Manual) on the TSX of common shares not directly or indirectly owned by insiders of Globex, in accordance with the policies of the TSX. Globex intends to acquire the common shares because it believes that the repurchase of common shares at certain market prices is beneficial to Globex and its shareholders. Globex intends to make any purchases on an opportunistic basis, taking share price and other considerations into account. Any purchases made pursuant to the NCIB will be made in accordance with the requirements of the TSX. Except for exempt offers, Globex will make no purchases of common shares other than open market purchases during the period of the NCIB. Under its current NCIB, which entered into effect on August 2, 2024 and which expires on August 1, 2025, Globex is authorized to purchase up to 1,000,000 shares. Under the NCIB, Globex has repurchased a total of 169,200 common shares at a volume weighted average purchase price of $0.8971 per share, through the facilities of the TSX and on alternative trading systems in Canada. All of the repurchased shares were cancelled by Globex. In connection with the NCIB, Globex has entered into an automatic share purchase plan with a Canadian securities dealer pursuant to which the securities dealer, acting as Globex's agent, may acquire at its discretion shares on Globex's behalf during 'black-out' or 'closed' periods under Globex's stock trading policy, subject to certain parameters as to price and number of shares. Forward Looking Statements Except for historical information, this news release may contain certain 'forward looking statements'. These statements may involve a number of known and unknown risks and uncertainties and other factors that may cause the actual results, level of activity and performance to be materially different from the expectations and projections of Globex Mining Enterprises Inc. ('Globex'). No assurance can be given that any events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits Globex will derive therefrom. A more detailed discussion of the risks is available in the 'Annual Information Form' filed by Globex on SEDAR+ at . 56,095,636 shares issued and outstanding
Cision Canada
21-07-2025
- Business
- Cision Canada
ALIMENTATION COUCHE-TARD REINITIATES SHARE REPURCHASE PROGRAM USA - English USA - English USA
LAVAL, QC, July 21, 2025 /CNW/ - Alimentation Couche-Tard Inc. (" Couche‑Tard") (TSX: ATD) announced today that the Toronto Stock Exchange (" TSX") has approved the share repurchase program (the " Program"), authorizing Couche‑Tard to repurchase up to 77,115,921 Common Shares (the " Shares"), representing 10% of the 771,159,210 Shares comprising Couche-Tard's "public float" (as such term is defined in the TSX Company Manual) as at July 14, 2025. Based on the current share price the completion of the Program in full would represent a total investment of approximately US $4.2 billion or CDN $5.8 billion. As at July 14, 2025, there were 948,064,405 Shares issued and outstanding. The average daily trading volume for the six-month period preceding June 30, 2025 represents 1,316,554 Shares. In accordance with TSX requirements, Couche-Tard is entitled to purchase, on any trading day, up to a total of 329,138 Shares representing 25% of this average daily trading volume. Couche-Tard believes that the purchase of up to 77,115,921 Shares under the Program is an appropriate use of its funds and a desirable investment for Couche-Tard and, therefore, would be in the best interests of Couche-Tard. By making such repurchases, the number of Shares in circulation will be reduced and the proportionate interest of all remaining shareholders in the share capital of Couche-Tard will be increased on a pro rata basis. "With a strong balance sheet and confidence in our long-term strategy, we believe this program represents an efficient way to create long-term shareholder value," said Filipe Da Silva, Chief Financial Officer. Under the terms of the Program, Couche-Tard may repurchase up to 77,115,921 Shares on the open market through the facilities of the TSX and through alternative trading systems in Canada, as well as outside the facilities of the TSX pursuant to exemption orders issued by securities regulators, over the course of twelve months commencing July 23, 2025 and ending at the latest on July 22, 2026. All Shares will be purchased at their market price at the time of acquisition, except for purchases effected outside the facilities of the TSX pursuant to exemption orders issued by securities regulators which will be at a discount to the market price as provided in such exemption orders. The actual number of Shares purchased under the Program, the timing of purchases and the price at which the Shares are bought will depend upon management discretion based on factors such as market conditions. All Shares repurchased under the Program will be cancelled upon their repurchase. Under Couche-Tard's previous Program which commenced on May 1, 2024 and expired on April 30, 2025, Couche-Tard obtained approval from the TSX to repurchase for cancellation up to 78,083,521 Shares. During the past 12 months, Couche-Tard repurchased 8,695,652 Shares outside the facilities of TSX by way of private agreement in reliance upon a decision obtained from the Autorité des marchés financiers to exempt the issuer from issuer bid requirements under applicable securities legislation, and such Shares were acquired at a price of CAD $80.50 per Share. In connection with the Program, Couche-Tard has established an automatic share purchase plan ("ASPP") with a designated broker whereby Shares may be repurchased at times when such purchases would otherwise be prohibited pursuant to regulatory restrictions or self-imposed blackout periods. Under the ASPP, before entering a self-imposed blackout period, Couche-Tard may, but is not required to, ask the designated broker to make purchases under the Program. Such purchases will be made at the discretion of the designated broker, within parameters established by Couche-Tard prior to the blackout periods. Outside the blackout periods, purchases will be made at the discretion of Couche-Tard's management. The ASPP will constitute an "automatic plan" for purposes of applicable Canadian securities legislation and has been pre-cleared by the TSX. About Alimentation Couche-Tard Inc. Couche-Tard is a global leader in convenience and mobility, operating in 29 countries and territories, with close to 17,000 stores, of which approximately 13,000 offer road transportation fuel. With its well-known Couche-Tard and Circle K banners, it is one of the largest independent convenience store operators in the United States and it is a leader in the convenience store industry and road transportation fuel retail in Canada, Scandinavia, the Baltics, Belgium, as well as in Ireland. It also has an important presence in Luxembourg, Germany, the Netherlands, Poland, as well as in Hong Kong Special Administrative Region of the People's Republic of China. Approximately 146,000 people are employed throughout its network. For more information on Alimentation Couche-Tard Inc., or to consult its audited annual Consolidated Financial Statements, and Management Discussion and Analysis, please visit: Forward-Looking Statements This press release may include certain statements that are "forward-looking information" within the meaning of the securities laws of Canada, including statements relating to the Program. Any statement in this press release that is not a statement of historical fact may be deemed to be forward-looking information. When used on this press release, the words "believe", "could", "should", "intend", "expect", "estimate", "assume", "aim", "align", "maintain", "continue", "effect", "growth", "position", "seek", "strategy", "strive", "will", "may", "might" and other similar expressions or the negative of these terms are generally intended to identify forward-looking information, although not all forward-looking statements include such words. These statements are based on management's current expectations, assumptions and estimates, which it believes are reasonable, but which are subject to a number of risks and uncertainties that could cause actual results and outcomes to differ materially, including risks associated with market and economic conditions, future plans and projections, and regulatory trends and changes, and such other risks as described in detail from time to time in documents filed by Couche-Tard with securities regulatory authorities in Canada. All forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement and speak as of the date of this news release. Couche-Tard undertakes no obligation to publicly update such forward-looking information to reflect new information, subsequent or otherwise, unless required by applicable securities laws. SOURCE Alimentation Couche-Tard Inc.
Cision Canada
15-07-2025
- Business
- Cision Canada
Coveo Announces Renewal of Normal Course Issuer Bid and Automatic Securities Purchase Plan Français
, July 15, 2025 /CNW/ - Coveo Solutions Inc. (" Coveo" or the " Company") (TSX: CVO), the leader in AI-Relevance, delivering best-in-class AI-search and generative experiences that maximize business outcomes at every point-of-experience, announced today that its board of directors has authorized, and the Toronto Stock Exchange (" TSX") has approved, Coveo's notice of intention to renew its normal course issuer bid (the " NCIB") to purchase for cancellation up to 5,423,244 subordinate voting shares (" Shares") over the twelve-month period commencing on July 17, 2025 and ending no later than July 16, 2026, representing approximately 10% of the "public float" of the Shares as at July 4, 2025. As at July 4, 2025, 55,730,805 Shares were issued and outstanding, of which 54,232,443 constituted the "public float". The renewal of the NCIB follows on the conclusion of Coveo's previous normal course issuer bid which expires on July 16, 2025 (the " Previous NCIB"). Coveo had received the approval of the TSX to purchase up to 2,690,573 Shares under the Previous NCIB. From July 17, 2024 to July 16, 2025, Coveo purchased the full 2,690,573 Shares authorized by the TSX under the Previous NCIB, through open market purchases on the TSX and Canadian alternative trading systems, with Shares purchased at a weighted average price of C$6.43 per Share. The NCIB will be conducted through the facilities of the TSX or alternative Canadian trading systems and will conform to their regulations. Shares will be acquired under the NCIB at the market price at the time of purchase. Purchases under the NCIB will be made by means of open market transactions, including through privately negotiated transactions or such other means as a securities regulatory authority may permit. In the event that the Company acquires Shares by other means as a securities regulatory authority may permit, the purchase price of the Shares may be different than the market price of the Shares at the time of the acquisition. Purchases made under an issuer bid exemption order will be at a discount to the prevailing market price as per the terms of the order. Furthermore, under the NCIB, Coveo may make, once per week, a block purchase (as such term is defined in the TSX Company Manual) at market price, in accordance with TSX rules. Under TSX rules, block purchases may not be made, directly or indirectly, from any insider of the Company, including shareholders of Coveo holding more than 10% of the Shares or the Multiple Voting Shares. Coveo will otherwise be allowed to purchase daily, through the facilities of the TSX, a maximum of 33,606 Shares representing 25% of the average daily trading volume, as calculated per the TSX rules for the six-month period starting on January 1, 2025 and ending on June 30, 2025. Coveo also announced today that, in connection with its intention to renew the NCIB, it has renewed its automatic share purchase plan (the " ASPP") with a designated broker to allow for the purchase of its Shares under the NCIB, once effective, at times when Coveo normally would not be active in the market due to applicable regulatory restrictions or internal trading black-out periods. Before the commencement of any internal trading black-out period, Coveo may, but is not required to, instruct its designated broker to make purchases of Coveo's Shares under the NCIB during the ensuing black-out period in accordance with the terms of the ASPP. Such purchases will be determined by the broker in its sole discretion based on parameters established by Coveo prior to commencement of the applicable black-out period in accordance with the terms of the ASPP and applicable TSX rules. Outside of these black-out periods, Shares will be purchasable by Coveo at its discretion under the NCIB, once effective. The ASPP constitutes an "automatic securities purchase plan" under applicable Canadian securities laws. Coveo is renewing its NCIB as it provides it with a capital allocation alternative, with a view to continue to create long-term shareholder value. Coveo's board of directors and management believe that the market price of the Shares may from time to time not reflect the underlying value of the Shares, and purchases of Shares for cancellation under the NCIB provides both (i) an opportunity to enhance shareholder value, as purchasing Shares for cancellation through an NCIB increases each shareholder's relative equity interests in Coveo, and (ii) liquidity to selling shareholders in the market. The actual number of Shares purchased under the NCIB, the timing of purchases and the price at which the Shares are purchased will depend on various factors, including Coveo's capital and liquidity positions, accounting and tax considerations, Coveo's operational performance, alternative uses of capital, the trading price of the Shares on the TSX, and market conditions. This press release is for informational purposes only and does not constitute an offer to buy or the solicitation of an offer to sell Coveo's shares. Forward-Looking Information This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities laws, including statements relating to the NCIB (including purchases thereunder, the price, timing and size of such purchases, and the implementation of an ASPP), and other statements that are not historical facts (collectively, "forward-looking information"). This forward-looking information is identified by the use of terms and phrases such as "may", "would", "should", "could", "might", "will", "achieve", "occur", "expect", "intend", "estimate", "anticipate", "plan", "foresee", "believe", "continue", "target", "opportunity", "strategy", "scheduled", "outlook", "forecast", "projection", or "prospect", the negative of these terms and similar terminology, including references to assumptions, although not all forward-looking information contains these terms and phrases. In addition, any statements that refer to expectations, intentions, projections, or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management's expectations, estimates, and projections regarding future events or circumstances. Forward-looking information is necessarily based on a number of opinions, estimates, and assumptions that we considered appropriate and reasonable as of the date such statements are made. Although the forward-looking information contained herein is based upon what we believe are reasonable assumptions, actual results may vary from the forward-looking information contained herein. Forward-looking information is subject to known and unknown risks, uncertainties, and other factors, many of which are beyond our control, that may cause the actual results, level of activity, performance, or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to macro-economic uncertainties and the risk factors described under "Risk Factors" in the Company's most recently filed Annual Information Form available under our profile on SEDAR+ at There can be no assurance that such forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information, which speaks only as of the date made. Moreover, we operate in a very competitive and rapidly changing environment. Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. You should not rely on this forward-looking information, as actual outcomes and results may differ materially from those contemplated by this forward-looking information as a result of such risks and uncertainties. Except as required by law, we do not assume any obligation to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. About Coveo Coveo brings superior AI-Relevance to every point-of-experience, transforming how enterprises connect with their customers and employees to maximize business outcomes. Relevance is about moving from persona to person, the degree to which the enterprise-wide content, products, recommendations, and advice presented to a person online aligns easily with their context, needs, preferences, behavior and intent, setting the competitive experience gold standard. Every person's journey is unique, and only AI can solve the complexity of tailoring experiences across massive, diverse audiences and large volumes and variety of content and products. Our Coveo AI-Relevance ™ Platform enables enterprises to deliver hyper-personalization at every point-of-experience, unifying all their data securely, with the highest level of contextual and prescriptive accuracy while simultaneously optimizing business outcomes. Coveo brings AI-Relevance to the digital experiences of many of the world's premier and most innovative brands, serving millions of people across billions of interactions. What we believe is bold: Digital is everywhere, Relevance is not. It's the only way to win in the digital age. The Coveo AI-Relevance Platform is ISO 27001 and ISO 27018 certified, SOC2 compliant, HIPAA compatible, with a 99.999% SLA available. We are a Salesforce ISV Partner, an SAP Endorsed Ⓡ App, AWS ISV Accelerate Program member, an Adobe Gold Partner, MACH Alliance member, Optimizely Partner, Shopify Partner, and a Genesys AppFoundry Ⓡ ISV Partner. Coveo is a trademark of Coveo Solutions Inc.
